Loading the content... Loading depends on your connection speed!

Enter New Email
Confirm New Email
Enter Old Password
Enter New Password
Confirm New Password
 
Email sent successfully to:
Algorithm Information

Risk Factors for Interstitial Lung Disease Following Gefitinib Therapy

MyLikes

MyPaths
Purpose:
To identify a patient with a non-small cell lung cancer (NSCLC) who may be at risk for interstitial fibrosis following gefitinib therapy.
Specialty
  • Hematology Oncology
    Pulmonology
Objective
  • Risk factors
  • Adverse effects
ICD-10
  • T45.1
MyPaths
Cancel
Create Path
Create
Cancel
Create Note
Save
Risk Factors for Interstitial Lung Disease Following Gefitinib Therapy
Cancel
Save Data
Save
Limitation to 5 characters is for patient privacy.